24.09.2025 | Pharmaceutical innovation is at a turning point. The current batch production of nanomedicines is costly, inconsistent, and time-consuming. Challenges such as limited stability, cold-chain requirements, and high unit costs continue to severely restrict access to these life-saving nanomedicines.
